Clinical pharmacodynamics of antifungals

Infectious Disease Clinics of North America

Volumn 17, Issue 3, 2003, Pages 635-649

  Andes, David ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; POLYENE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0346433672     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(03)00063-1     Document Type: Review

References (57)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
2. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9.
3. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
4. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 2000;3:515-21.
5. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters: approved guidelines. 2nd edition. Document M23-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
6. Andes D, van Ogtrop ML. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis model. Antimicrob Agents Chemother 1999;43:2116-20.
7. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2001;45: 922-6.
8. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000;44:938-42.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeast; approved standard. M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
10. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11.
11. Klepser ME, Wolfe EJ, Jones RN, Nightengale CH, Pfaller MA. Antifungal pharmacodynamic characterization of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5.
12. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002;46:1857-69.
13. Walsh TJ, Lee JW, Roilides E, et al. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis 1992;14:S139-47.
14. Andes D, Marchillo K, Lowther J, et al. In-vivo characterization of the pharmacodynamics of HMR 3270, a glucan-synthase inhibitor in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1187-92.
15. Andes D. In vivo pharmacodynamics of antifungal drugs in the treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-86.
16. Andes D, Marchillo K, Stamstad T. In vivo characterization of the pharmacodynamics of a new triazole, ravuconazole in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1193-9.
17. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th edition. Baltimore: Williams and Wilkins; 1996. p. 296-329.
18. Turnidge JD, Gudmondsson S, Vogelman B, Craig WA. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994; 34:83-92.
19. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-8.
20. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw M, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105-9.
21. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. 4th edition. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins; 1996. p. 367-402.
22. Kunin CM, Craig WA, Kornguth M, Monson R. Influence of binding on the pharmacological activity of antibiotics. Ann N Y Acad Sci 1973;226:214-24.
23. Dowell SF, Butler JC, Geibink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Working Group. Pediatr Infect Dis J 1999;18:1-9.
24. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis 2000;123:1-32.
25. www.FDA.gov. Accessed 2001.
26. Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1986;30:418-22.
27. Sorensen K, Corcoran E, Chen S, et al. Pharmacodynamic assessment of efflux- and target-based resistance against C. albicans in a mouse kidney infection model [abstract 1271]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999.
28. Van't Wout J, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989;33:147-51.
29. Craig WA, Dalhoff A. Pharmacodynamics of fluoroquinolones in experimental animals. In: Kuhlmna J, Dalhoff A, Zeiller HJ, editors. Handbook of experimental pharmacology: quinolone antibacterials, vol. 127. Heidelberg: Springer; 1998:207-32.
30. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
31. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al, for the NCCLS Subcommittee on Antifungal Susceptibility Testing. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
32. Rex JH, Pfaller MA, Walsh TJ, Charurvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001;14:643-58.
33. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole resistant candidiasis in an HIV cohort. AIDS 1994;8:787-92.
34. Barchiesi F, Hollis RJ, McGough DA, Scalise G, Rinaldi MG, Pfaller MA. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis 1995;20:634-40.
35. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993;31:2933-7.
36. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.
37. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:2495-7.
38. Heinic GS, Stevens DA, Greenspan D, MacPhail LA, Dodd CL, Stringari S, et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. Oral Surg Oral Med Oral Pathol 1993;76:711-5.
39. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-6.
40. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
41. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, et al. Resistance to Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in patients with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
42. Reynes J, Mallie M, Andre D, Janbon F, Bastide JM. Traitement et prophylxie secondarire par fluconazole des candidoses oropharyngees des suets VIH+. Analyse mycologique des echecs. Pathol Biol 1992;40:513-7.
43. Rodriguez-Tudela JL, Laguna F, Martinez-Suarez JV, Chaves R, Dronda F. Fluconazole resistance of Candida albicans isolates from AIDS patients receiving prolonged antifungal therapy [abstract 1204]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 1992. p. 311.
44. Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 1994;22:132-6.
45. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32:2092-8.
46. Sandven P, Bjorneklett A, Maeland A. Norwegian Yeast Study Group. Susceptibility testing of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother 1993;37:2443-8.
47. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-45.
48. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996;34:489-95.
49. Cartledge JD, Midgley J, Petrou M, Shanson D, Gazzard BG. Unresponsive HIV-related oro-oesophageal candidosis: an evaluation of two new in vitro azole susceptibility tests. J Antimicrob Chemother 1997;40:517-23.
50. Dannaoui E, Colin S, Pichot J, Piens MA. Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis. Eur J Clin Microbiol Infect Dis 1997;16:228-32.
51. Revankar SG, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;26:960-3.
52. Quereda C, Polanco AM, Giner C, Sanchez-Souza A, Pereira E, Navas E, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:30-7.
53. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. NIAID Mycoses Study Group and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
54. Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen NL, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000;44:2715-8.
55. Clancy CJ, Kauffman CA, Morris A, Nguyen ML, Tanner DC, Snydman DR, et al. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp.: results of a multicenter prospective study of candidemia [abstract 98]. In: Program and abstracts of the Infectious Diseases Society of America, 36th Annual Meeting. Alexandria (VA): Infectious Disease Society of America; 1998. p. 93.
56. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7.
57. Purkins L, Wood N, Ghahramini P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.